Prognostic analysis of patients with metastatic triple-negative breast cancer: A report of 120 cases

National Medical Journal of China

Volumn 90, Issue 40, 2010, Pages 2848-2851

  Miao, Pei Tian ^a   Tong, Zhong Sheng ^a   Hao, Chun Fang ^a   Zhang, Li ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Metastasis; Prognosis; Triple negative breast neoplasms

Indexed keywords

ARTICLE; BRAIN METASTASIS; BREAST METASTASIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; TRIPLE NEGATIVE BREAST CANCER; ADULT; AGED; BRAIN TUMOR; BREAST TUMOR; CANCER STAGING; FEMALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84871432949     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.40.011     Document Type: Article

References (11)

1. Haffty B G, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 2006, 24: 5652-5657.
2. Dent R, Trudeau M, Pritchard K I, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 2007, 13: 4429-4434.
3. Cleator S, Heller W, Coombes R C, et al. Triple-negative breast cancer: therapeutic options. Lancet Oncol, 2007, 8: 235-244.
4. Rakha E A, El-Sayed M E, Green A R, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109: 25-32.
5. Tischkowitz M, Brunet J S, Begin L R, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 2007, 7: 134.
6. Barnholtz-Sloan J S, Sloan A E, Davis F G, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J Clin Oncol, 2004, 22: 2865-2872.
7. Lin N U, Winer E P. Brain metastases: the HER2 paradigm. Clin Cancer Res, 2007, 13: 1648-1655.
8. Fulford L G, Reis-Filho J S, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res, 2007, 9: R4.
9. Lin N U, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer-high incidence of central nervous system metastases. Cancer, 2008, 113: 2638-2645.
10. Heitz F, Harter P, Lueck H J, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer, 2009, 45: 2792-2798.
11. Yonemori K, Tsuta K, Ono M, et al. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer, 2010, 116: 302-308.